Aspirin (Acetylsalicylic acid, BAYe4465) + Aspirin (Acetylsalicylic acid, BAYe4465) + Aspirin (Acetylsalicylic acid, BAYe4465)
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pharmacology, Clinical
Conditions
Pharmacology, Clinical
Trial Timeline
Feb 1, 2015 → Mar 1, 2015
NCT ID
NCT02394093About Aspirin (Acetylsalicylic acid, BAYe4465) + Aspirin (Acetylsalicylic acid, BAYe4465) + Aspirin (Acetylsalicylic acid, BAYe4465)
Aspirin (Acetylsalicylic acid, BAYe4465) + Aspirin (Acetylsalicylic acid, BAYe4465) + Aspirin (Acetylsalicylic acid, BAYe4465) is a phase 1 stage product being developed by Bayer for Pharmacology, Clinical. The current trial status is completed. This product is registered under clinical trial identifier NCT02394093. Target conditions include Pharmacology, Clinical.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02394093 | Phase 1 | Completed |
Competing Products
16 competing products in Pharmacology, Clinical